A statewide multi-institutional model that de-risks academic drug discovery

Drug Discov Today. 2026 May;31(3):104685. doi: 10.1016/j.drudis.2026.104685. Epub 2026 Apr 29.

Abstract

Texas has built a coordinated, multi-institution core network that de-risks academic discoveries while reducing redundant rebuilds across institutions. Through a distributed drug R&D model, autonomous cores collaborate via shared forums and referrals, making handoffs routine and providing industry-grade capabilities within academic settings. By preserving local expertise while enabling cross-core progression when data warrant, the network has delivered measurable outcomes: in a 2024 survey of ten cores, >750 projects entered at least one core, >70 traversed multiple cores, ∼25 patents were filed, >60 startups launched and 15 programs reached the clinic; projects also attracted >US$186M in non-dilutive and >US$400M in dilutive capital. Together, these results demonstrate that collaboration at scale through a distributed core model can deliver meaningful translational impact.

Keywords: Academic drug discovery and development; IND acceleration and de-risking; Texas biotech ecosystem; commercialization mentor/advisor network; drug R&D infrastructure; multi-institutional core network; workforce training and education.

Publication types

  • Review

MeSH terms

  • Academia
  • Cooperative Behavior
  • Drug Discovery* / organization & administration
  • Humans
  • Texas